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INTRODUCTION 
The cornea has the unique feature of being normally avascular 
except for   small loops which invade the periphery for about 1mm. But 
under pathologic conditions vessels invade the cornea from the limbal 
vascular plexus. A wide variety of insults including 
  infection,  
  inflammation,   
  ischemia,  
  degeneration, 
  trauma, and  
          loss of the limbal stem cell barrier can cause corneal 
neovascularization. Although corneal NV can occasionally serve a 
beneficial  role in the clearing of infections, wound healing, and in 
arresting stromal melts, its disadvantages are numerous. Corneal NV 
often leads to tissue scarring,  Oedema, lipid deposition, and persistent 
inflammation that may significantly  alter visual acuity. Corneal NV 
accompanies the most common causes of  corneal infectious blindness 
in both the developed (herpetic keratitis) and  developing (trachoma and 
onchocerciasis) world, which cause millions to lose  their sight.  
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Neovascularization is divided into two main processes; 
Vasculogenesis and Angiogenesis. The former Vasculogenesis is the 
formation of new blood vessels from bone marrow derived angioblast, 
while the latter is formation of new blood vessels from already present 
vascular structures.1 
  Corneal NV may not only reduce visual acuity but also it results 
in the loss of the immune privilege of the cornea, thereby worsening the 
prognosis of subsequent penetrating keratoplasty (PK). Pre-existing 
corneal stromal blood vessels have been identified as strong risk factor  
for immune rejection after corneal transplantation. Although various 
compounds have been shown to inhibit corneal neovascularization in 
experimental and clinical situations including steroids, indomethacin, 
cyclosporine, methotrexate, low molecular weight heparin sulphate, 
rapamycin and thalidomide there is still no clear consensus about the 
best treatment of corneal neovascularization. Although steroids are the 
mainstay of treatment in corneal neovascularization, they are not always 
effective and without complications1.  
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FUNCTIONAL ANATOMY & FINE STRUCTURE OF 
CORNEA 
The cornea is a transparent, avascular, watch glass like structure. 
It forms anterior one sixth of the outer fibrous coat of the eyeball.  Has 
five layers Epithelium, Bowman’s membrane, Stroma, Descemet’s 
membrane, and Endothelium. 
 
 
 
 
 
 
 
 
Fig. 1 Layers Of the cornea 
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EPITHELIUM 
           Corneal epithelium is of stratified squamous type and becomes 
continuous with epithelium of bulbar conjunctiva at the limbus. It is 
about 50 – 90 micrometer thickness and consists of 5 – 6 layers of cells. 
The deepest basal layer is made up of columnar cells, next 2 – 3 layers 
of wing or umbrella cells and the more superficial 2 layers are of 
flattened cells. The corneal epithelium sheds at irregular intervals and is 
replaced by growth from its basal cells. It is estimated that the entire 
epithelium is replaced in a period of 6 – 8 days. 
BOWMAN’S MEMBRANE 
This layer consists of acellular mass of condensed collagen fibrils. 
It is about 8 – 14 micrometer in thickness and binds the corneal stroma 
anteriorly with basement membrane of the epithelium. It is not a true 
elastic membrane but simply a condensed superficial part of the stroma. 
It shows considerable resistance to infection and injury. But once 
destroyed does not regenerate. 
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STROMA (SUBSTANTIA PROPRIA)   
This layer is about 0.5mm in thickness and constitutes most of the 
cornea (90% of total thickness). It consists of collagen fibrils (lamellae) 
and cells embedded in hydrated matrix of proteoglycans.  
The lamellae are arranged in many layers, in each layer they are 
not only parallel to each other but also to the corneal plane and become 
continuous with the scleral lamella at the limbus. They vary in 
disposition according to the area of the cornea. They have oblique 
orientation in the anterior 1/3rd of the stroma. In the posterior 2/3rd of the 
stroma the alternating layer of lamella are at right angles to each other. 
         
Fig 2. Histology of cornea 
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The parallel arrangement of lamella in the cornea allows an easy 
intralamellar dissection during superficial keratectomy and lamellar 
keratoplasty. The peculiar arrangement of lamellae has also been 
implicated in the corneal transparency. 
  The cells among the lamellae are present keratocytes, wandering 
macrophages, histiocytes and few lymphocytes. The corneal keratocytes 
constitute 2 – 4 % of the volume of the stroma in humans. The 
keratocytes are fibroblasts which are found throughout the stroma, 
between, and occasionally extending into the lamella. 
The keratocytes have a flattened cell body, a large eccentric 
nucleus and long branching processes which form contact with other 
cells in the same layer but do not form a syncytium. It is believed that 
these cells produce ground substance and collagen fibrils during 
embryogenesis and after injury. The wandering cells of the stroma 
migrate from the marginal loops of the corneal blood vessels. 
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DESCEMET’S MEMBRANE (POSTERIOR ELASTIC LAMINA)  
 It is a strong homogenous layer which binds the stroma 
posteriorly. It represents the basement membrane of the endothelium 
from which it is produced. Though elasticity is one of its physical 
characteristics, it is made up of collagen and glycoprotein with no 
elastic fibers visible by electron microscopy. Its thickness varies with 
age being 3µm at birth and 10 – 12 µm in young adults. It is very 
resistant to chemical agents, trauma, infection and pathological 
processes. Even when whole of the stroma is sloughed off, the 
descemet’s membrane can maintain the integrity of the eyeball for a 
long. Further, unlike bowman’s membrane when destroyed, it can 
regenerate. Normally it remains in a state of tension and when  torn it 
curls inwards on itself. In the periphery it appears to end at the anterior 
limit of the trabecular meshwork as schwalbe’s line. 
ENDOTHELIUM 
 It consists of single layer of flat polygonal cells which on slit 
lamp biomicroscopy appear as mosaic. The cell density of endothelium 
is around 6000 cells/mm2 at birth. The cell count falls by about 26% in 
the first year and a further 26% is lost over the next 11 years. Therefore, 
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with increasing age, the number of cells is reduced to 2400 – 3000cells/ 
mm2 in young adults. The deficit left by the dying cells is filled by 
enlargement (polymegathism) of the remaining cells. Hence, these cells 
vary in diameter from 18 – 20 µ early in life to 40 µ or more in the aged. 
  There is a considerable functional reserve for the endothelium. 
Therefore, corneal decompensation occurs only after more than 75% of 
adult age cells are lost (ie. when the endothelial cell count becomes less 
than 500 cells/mm2). The endothelial cells are attached to the descemet’s 
membrane by hemidesmosomes and laterally to each other by tight 
junctional complexes. The desmosomal linkages and zonulae 
occludentes are continuous around the entire cell and thus close the 
intercellular space form the anterior chamber. 
This linkage is calcium dependant and plays an important role in 
maintaining the barrier function of the endothelium. The endothelium 
also contains an active pump mechanism and is involved in active 
secretion and protein synthesis.  
The high metabolic activity and energy production for the above 
process by the endothelial cells is evidenced by the presence of 
abundant mitochondria, free ribosome’s, rough and smooth surface 
17 
 
endoplasmic reticulum and golgi complexes in the cytoplasm of these 
cells. In the eye, next to photo receptors, the endothelial cells contain 
highest number of mitochondria. 
SOURCES OF NUTRIENTS 
OXYGEN 
  The epithelium derives oxygen mainly from atmosphere through 
the tear film (active process) as well as through the limbal capillaries. 
The oxygen required by the epithelium is about one –tenth of that 
available from the atmosphere when the eyes are open and about one-
fourth of that available from the palpebral conjunctiva when the eyes are 
closed. 
            The endothelium derives most of its required oxygen from the 
aqueous humour which has an oxygen tension of 72mmHg.  
The major metabolic pathways in the cornea are Glycolysis and 
Kreb’s cycle. 
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METABOLISM OF CORNEA 
The cornea among other activities requires energy for 
maintenance of its transparency and dehydration. Energy in the form of 
ATP is generated by the breakdown of glucose. The most actively 
metabolising layers of the cornea are epithelium and endothelium, the 
former being ten times thicker than the latter thus requiring a 
proportionally larger supply of metabolic substrates. 
PATHOGENESIS OF CORNEAL NEOVASCULARISATION 
The factors that keep the cornea avascular are unknown and so is 
the pathogenesis of corneal vascularisation. However various theories 
which have been proposed largely agree on the role of chemical and 
mechanical factors in producing corneal neovascularisation. 
Chemical Theory 
There may be presence of vasostimulatory (VSF) factor or the 
breaking down of previously existing vasoinhibitory factor (VIF). 
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Role of Vasoinhibitory Factor 
The idea that avascularity of the cornea might be due to the 
presence of a vasoinhibitory factor preventing vascular invasion was put 
forward by Meyer and Chafre.   
Angiogenic stimulators and inhibitors are the counterbalancing 
systems that tightly control corneal angiogenesis. The healthy cornea is 
devoid of vascular elements and is maintained as an immune-privileged 
site.  
This immunity is thought to be due to the plethora of 
antiangiogenic factors present in this tissue. These include pigment 
epithelium–derived factor (PEDF), maspin, thrombospondin, endostatin, 
a proteolysis product of type XVIII collagen; and angiostatin, a 
proteolysis product of plasminogen. 
   The class B scavenger receptor CD362 is a transmembrane 
glycoprotein that has been identified as the critical receptor for 
thrombospondin (TSP)-1, a potent endogenous inhibitor of 
angiogenesis, including that which occurs in the cornea. CD36 also 
binds to a variety of other ligands including oxidized low- density 
lipoproteins, oxidized phospholipids, Plasmodium falciparum–infected 
erythrocytes, collagen, and apoptotic cells. 
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Expression of CD36 is broad and encompasses micro vascular 
endothelial cells, monocytes/macrophages, platelets, conjunctival 
dendriform cells, and the retinal pigment epithelium. Furthermore, 
CD36 has been implicated  in a wide variety of normal and  abnormal 
biological functions, including angiogenesis, atherosclerosis, 
phagocytosis, inflammation, lipid metabolism, and removal of apoptotic 
cells. 
With respect to its angiostatic functions, CD36 is essential for 
inhibiting in vitro endothelial cell migration and the formation of 
capillary-like structures by TSP-1. CD36 plays a critical role in vivo, as 
demonstrated by the inability of TSP-1 to inhibit angiogenesis in CD36 
null mice. It has also been  recently demonstrated the specific 
involvement of CD36 and TSP-1 in mediating anti- angiogenic signals 
in ischemic proliferative retinopathy3.  
Nevertheless, the involvement of CD36 and the relative role of its 
less well-characterized oxidized lipid-binding site in regulating 
pathologic corneal angiogenesis have not yet been fully elucidated4.  
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Role of Vasostimulatory Factor 
Campell and Michaelson 1949 using experimental corneal burns 
in animals postulated the release of vasostimulatory factor at the site of 
leision which diffuses through the stroma to the limbus and stimulates 
new vessel growth from the limbal plexus. It has also been postulated 
that hypoxia also induces neovascularisation by activation of 
vasostimulatory factor. 
Mechanical Theory 
Cogan postulated that blood vessel cannot invade normal cornea 
because of its compact structural nature and that loosening of the 
compactness of corneal tissue due to oedema was mandatory for 
neovascularisation. This mechanical theory was agreed to by many 
workers. However, Langham doubted the adequacy of oedema alone 
being responsible for neovascularisation. Clinically also it has been seen 
that in Fuch, s dystrophy and aphakic bullous keratopathy, it is rare for 
the vascularisation to occur even when the oedema extends to limbus. 
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Combined Mechanical and Chemical Theory 
Maurice et al have demonstrated that both  release of some 
vasostimulatory factor and loosening of compact corneal stroma by 
oedema are necessary for the neovascularisation to occur. 
ROLE OF LEUCOCYTES IN CORNEAL 
NEOVASCULARIZATION2  
There presently exists much experimental evidence supporting the 
hypothesis that leucocytes play a crucial role in corneal vascularisation. 
A comparative study was conducted on a wide spectrum of experimental 
models of corneal vascularisation including exposure of the cornea to 
noxious agents as alloxon, Sodium hydroxide and silver nitrate. Corneal 
vascularisation was also studied following the intracorneal injection of 
antigen into sensitized animals, as well as after the maintenance of 
animals on riboflavin deficient diets. In all these studies they observed 
that a leucocytic infiltration preceded the onset of  vascular invasion. 
The various models consistently displayed three distinct  phases with 
respect to the presence of leucocytes and blood vessels within the  
corneal stroma.  
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PREVASCULAR PHASE 
            Initially only leucocytes were observed in each avascular cornea. 
VASOPROLIFERATIVE PHASE 
             Prevascular phase was followed by a time span when both 
proliferating  capillaries and leucocytes were observed in the cornea 
simultaneously. 
ESTABLISHED PHASE 
          During this phase the leucocytes totally disappeared from the 
corneal stroma but the blood vessels remained. 
VASCULAR ENDOTHELIAL GROWTH FACTOR 
1. VEGF regulation and receptors 
  Vascular endothelial growth factor (VEGF) or vascular 
permeability factor is a secreted growth factor peptide of 45 kDa 
homodynamic glycoprotein that functions as an endothelial cell- specific 
mitogen and vasopermeability factor. It is activated by hypoxia, protein 
kinace C activation, advanced glycation products, reactive oxygen 
species, activated oncogens and variety of cytokines6. 
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Activation of VEGF induces proteolytic activities, endothelial cell 
proliferation, endothelial cell migration, capillary tube formation, 
induces vascular permeability, and inhibits apoptosis.  
 
 
 
 
 
 
 
 
 
 
Fig 3. Stages of vascularization 
In angiogenesis VEGF mediates the initial five steps 
i. disruption of basement membrane 
ii. migration 
iii. proliferation 
iv. differentiation and tube formation 
v. pruning by leucocytes 
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Whereas platelet derived growth factor mediates maturation and 
pericyte recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
 
Fig 4. .VEGF receptors 
 
Genetic knock out of the only a single VEGF allele leads to 
embryonic lethality demonstrating a critical contribution for VEGF in 
embryonic vasculogenesis. Interestingly modest over expresssion of 
VEGF also proved lethal to the embryo. These VEGF levels must be 
closely regulated for development to proceed normally. VEGF acts 
through binding through two receptor kinases, VEGF R-1, VEGF R-2 
which respond in typical fashion to ligand binding by activation of 
single transduction cascades. 
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VEGF R-2 is principally responsible for mediating effects of 
VEGF on angiogenesis and vascular permeability. VEGF R-1 has been 
implicated in mediating chemotaxis to VEGF, a process that may 
contribute to pathogenic angiogenesis, ransduction of matrix 
metalloprpteinases and release of hepatic pancreatic factors. Its 
functions may also include negative regulators of VEGF by sequestering 
it thereby making it less available to VEGF R-2.22 
     The VEGF molecular family consists of five members 
 1.Placental growth factor 
 2.VEGF A 
 3.VEGF B 
 4.VEGF C 
 5.VEGF D 
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Fig. 5. Vascular Endothelial Growth Factor Gene 
           There are at least 6 major known isoforms of VEGF that arise 
from alternate splicing of mRNA of a single gene; VEGF115, 
VEGF121, VEGF145, VEGF165, VEGF189, and VEGF 206. VEGF165 
is the predominant pathological isoform7. It plays a major angiogenic 
role in several ocular pathologies characterized by NV. It was recently 
shown that VEGF was up-regulated in inflamed and vascularised 
corneas in humans and animal models.  
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VEGF-A is expressed by macrophages in the inflamed cornea and 
is down regulated after activation of CD36. It is well known, however, 
that transmigrating and invading macrophages are closely associated 
with neovascularization and provide much of the requisite VEGF that 
drives this process .VEGF can be inhibited by blocking its production or 
receptors or the molecule itself in the extra cellular space. 
VEGF AND SYSTEMIC DISEASES8 
VEGF stimulated collateral blood vessel formation helps to 
preserve myocardial function during coronary arterial occlusion. Several 
observations including the fact that direct VEGF transfer therapies have 
proved to be effective in coronary heart disease as well as peripheral 
vascular disease suggests that VEGF plays a significant role in this 
adaptive process. Thus although anti VEGF therapies appear promising 
as a means of reducing neo vascular complications from ischemic ocular 
diseases, they also have a potential to decrease collateral vascular 
formation and thereby increase micro vascular complications associated 
with myocardial infarction and peripheral limb ischemia. 
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Over expression of VEGF has been observed in a variety of 
cancers and has been associated with a worse relapse free and over-all 
survival. 
VEGF and RETINAL VASCULAR DISEASE  
Levels of ocular VEGF are tightly correlated with both growth 
and permeability of new vessels. In patients with proliferative diabetic 
retinopathy in which tissue hypoxia promotes neovascularisation; levels 
of VEGF are elevated in ocular tissues. These elevated levels of VEGF 
decline when treatment with laser photocoagulation induces regression 
of neovascularisation. Elevated VEGF levels are seen also in patients 
with Branch and Central retinal vascular occlusions. 
VEGF IN HUMAN OCULAR FLUIDS 
The growth of neovascular vessels in response to retinal ischemia 
(factor X) was initially proposed by Michaelson almost half a century 
ago. More recently, corneal hypoxia and inflammation, which has been 
implicated in the pathogenesis of corneal neovascularization, was shown 
to cause increased expression of VEGF. Indeed, evidence suggests that 
VEGF is a major mediator of corneal neovascularization. In 1994, 
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Aiello and colleagues demonstrated high levels of VEGF in ocular fluid 
of patients with diabetic retinopathy and other vascular disorders. 
Further work by Aiello found that suppression of retinal 
neovascularisation was achievable in vivo by inhibition of VEGF using 
soluble VEGF receptor chimeric proteins. 
VEGF IN HUMAN CORNEAL TISSUE 
Philipp et al. Have shown that VEGF is expressed in all three 
layers of inflamed cornea. Including the epithelium, stroma, and 
endothelium. It is highly expressed in the vascular endothelial cells of 
limbal vessels and in newly formed vessels in the stroma and weakly in 
keratocytes. Therefore subconjunctival injection route will be better for 
the access of medication to limbal endothelial cells1.  
PLATELET DERIVED GROWTH FACTOR 
o PDGF-B is a growth factor structurally related to VEGF 
o  The contributions of PDGF-B to angiogenesis are mediated 
largely through its effects on mural cells such as pericytes and 
vascular smooth muscle cells  
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                     Fig. 6.  Role of PDGF in corneal  neovascularization 
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o Mural cells are recruited to the endothelium primarily in response 
to endothelial cells  
o Mural cells are recruited to the endothelium primarily in respose 
to endothelial cell-secreted PDGF-B, which activates receptors on 
the mural cells and stimulates their migration and proliferation. 
o Vasculature that is stably covered with mural cells is largely 
resistant to the  effects of VEGF withdrawal, making it less 
susceptible to therapeutic intervention with VEGF blocking 
agents. 
o Blocking VEGF and PDGF may provide improved efficacy in the 
treatment of established ocular neovascular lesions 
VEGF INHIBITION IN CORNEAL NEOVASCULARISATION 
In December 2004, Pegaptanib sodium became the first anti-
VEGF agent approved by the United States Food and Drug 
Administration (USFDA) for treatment of all neovascular AMD 
regardless of lesion composition 
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Pegaptanib (Macugen, Eyetech/Pfizer, Inc, New York, NY), is a 
pegylated aptamer that consists of an RNA oligonucleotide ligand that 
binds human VEGF 165, with high affinity and specificity. Pegaptanib 
does not block the other isoforms of VEGF. 
Bevacizumab is a full length, recombinant, humanized 
monoclonal antibody, directed against all VEGF isoforms. It was the 
first anti-VEGF agent approved by the FDA for systemic administration 
in treatment of colorectal cancers8. Unfortunately, systemic effects, such 
as, elevation of systolic blood pressure and the potential for systemic 
thromboembolic events were concerns in the cancer studies, and 
although the first case using systemic bevacizumab for AMD held 
promise, the potential for adverse effects was deemed risky. 
  In the summer of 2005, Rosenfeld pioneered the use of 
intravitreal fractionated dose of bevacizumab for retinopathy in AMD 
with impressive results. After that many experimental studies conducted 
on animals by artificially inducing neovascularization. 
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RATIONALE FOR ANGIOGENESIS INHIBITORS IN 
CORNEAL NEOVASCULARIZATION 
Animal studies have supported the role of VEGF in the 
pathogenesis of corneal neovascularisation.  In expermental models, 
increased levels of VEGFmRNA and protein and VEGF receptors have 
been demonstrated in corneal neovascularization. Human corneal 
buttons with New vessels have been  shown to have higher levels of 
VEGF and its receptors.VEGF inhibition therefore supress corneal 
neovascularization and help improve vision or increase the chance of 
transplant survival. Corneal neovascularization was induced in animals 
by following these three models,  
Corneal Micropocket Neovascularization Models 
In brief, an aliquot of bFGF or VEGF was added to 2 μL of 12% 
hydron polymer (poly-HEME) in ethanol. Four-microliter aliquots of the 
mixture were placed on parafilm (American National Can, Greenwich,) 
and allowed to dry to produce pellets, each containing 500 ng of bFGF 
or 100 ng of VEGF. A partial corneal incision was made at the limbus, 
and dissection to the corneal stroma was performed up to 4 mm from the 
limbus. The pellet was placed in this pocket2. 
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Alkali Induced-Corneal NV Model 
Induction of the alkali-induced corneal NV model was performed 
as described by Ormerod et al with some modifications. In brief, a 5.5-
mm-diameter circular filter disc was incubated with 20μL of  NaOH for 
60 seconds. The filter disc was then placed on the cornea surface of 
anesthetized rabbits under the surgical microscope for 30 seconds. The 
ocular surface was then irrigated with 25 ml of physiological saline2 9. 
Limbal Injury–induced Corneal NV Model 
The limbal injury–induced corneal NV model was produced by 
surgical removal of the circumferential limbal tissue 2 mm into the 
cornea and 3 mm into the conjunctiva. Superficial lamellar keratectomy 
was also performed to remove the entire corneal epithelium. In this 
model, corneal NV occurred within 2 weeks after surgery10 11. 
           These studies have proven the effectiveness of subconjunctival 
and topical bevacizumab on corneal neovascularisation by observing the 
regression of new vessels. 
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Ranibizumab, (Lucentis, Genentech Inc, San Francisco) is a 
fragment of a humanized monoclonal antibody directed towards all 
isoforms of VEGF-A. It has a molecular weight of 48KD and is 
produced by an E. coli – expression system. Its unique structure was 
specifically engineered for ocular diseases. Ranibizumab is made up of 
just the Fab fragment that was the basis for the full length antibody, 
bevacizumab and has been affinity matured to have a higher binding 
affinity for VEGF than bevacizumab has12. 
The binding of Ranibizumab to all isoforms of VEGF-A prevents 
dimerisation with the VEGF receptors on cell surfaces (VEGF R1 and 
VEGF R2), thus reducing vascular leakage, angiogenesis and 
endothelial cell proliferation. 
Both Ranibizumab and bevacizumab block all forms of VEGF. 
Nevertheless, they have distinct differences that offer each advantage 
over the other. One advantage of Ranibizumab is that, it lacks the Fc 
region of the antibody, making it less likely to cause complement 
mediated inflammation after injection. Ranibizumab has only one 
binding site for VEGF, while bevacizumab has two. 
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                       AN UPDATE ON BEVACIZUMAB 
Bevacizumab (Avastin, Genentech) is a full length humanized 
murine monoclonal antibody, directed against all the biologically active 
forms of VEGF – A. Bevacizumab, the first anti – VEGF drug to be 
approved by the FDA was developed as an intravenous therapy for 
cancer patients, because VEGF is one of the major angiogenic stimuli, 
responsible for neovascularisation in tumours12. 
  Anti – VEGF therapy has shown promising results in several 
forms of cancer but the drug is currently approved only for the treatment 
of metastatic colorectal cancer. When used in cancer therapy, 
bevacizumab is infused at a dose of 5 mg/kg body weight, every 2 
weeks until the patient dies or significant disease progression is 
observed. In clinical trials, the most common adverse event caused by 
bevacizumab was hypertension6&12. 
The first two agents Pegaptanib and Ranibizumab have been 
approved by the FDA for use in neovascular AMD. The third drug 
bevacizumab which is a full-length humanized antibody against VEGF, 
has been approved for use in oncology but is also widely used off-label 
to treat choroidal neovascularization, central retinal vein occlusion, 
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proliferative diabetic retinopathy, and iris neovascularization with 
encouraging results. Bevacizumab has now been widely adopted and is 
arguably part of the standard of care for the treatment of neovascular 
AMD for many patients12.  
 PHARMACOKINETICS OF INTRAVITREALLY 
ADMINISTERED BEVACIZUMAB              
In the retina/choroid and iris/ciliary body after intravitreal 
injection, bevacizumab concentration above IC50 was maintained for 
approximately 11.7 and 10.3 weeks, respectively, whereas that above 
500 ng/mL was maintained for 7.7 and 6.6 weeks. A recent report 
regarding long-term follow-up results for intravitreal bevacizumab 
treatment of neovascular age-related macular degeneration has described 
the mean number of injections during 1 year as 3.4. Thus, a single 
intravitreal injection of bevacizumab is active for approximately 3 
months. Many studies in rabbits showed bevacizumab concentration in 
the retina/choroid after intravitreal injection were maintained for 
approximately 3 months (11.7 weeks) in the effective range and were 
consistent with reinjection intervals in clinical situations.13  
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PHARMACOKINETICS OF SUBCONJUNCTIVALLY 
ADMINISTERED BEVACIZUMAB  
In general, drug injected into subconjunctival space has two fates: 
direct trans- scleral delivery into intraocular tissues or clearance via 
conjunctival blood and lymphatic flow. Since IgG has a relatively high 
scleral permeability and has the same molecular weight as bevacizumab, 
some of the bevacizumab injected into the subconjunctival space may 
penetrate intraocular tissues including the retina/choroid, iris/ciliary 
body, and vitreous via the sclera. The bevacizumab level in the 
retina/choroid and iris/ciliary body was maintained above IC50 for 8.6 
and 8.4 weeks, respectively, whereas it was maintained above 500 
ng/mL for 0.3 weeks in the iris/ciliary body. The sclera consists of 
collagen and elastin chains that create a fiber matrix in which the pore 
diameter and intracellular space may determine the permeability of 
drugs. Negatively charged drugs have been found to have higher 
permeability than those with positive charges in bovine and porcine 
sclera. Proteoglycans in the sclera are negatively charged, which may 
contribute to the binding of positively charged molecules. An isoelectric 
point of bevacizumab has been found to be approximately 8.4. 
Therefore, longer T½ in the iris/ciliary body and retina/choroid after 
subconjunctival injection compared with those after intravitreal injection 
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may sustain bevacizumab delivery into intraocular tissues due to scleral 
depot binding of bevacizumab to the scleral matrix.4&13  
Since the conjunctival blood vessels do not form a tight junction 
barrier, bevacizumab can enter into the blood circulation by pinocytosis 
and/or convective transport through paracellular pores in the vascular 
endothelial layer. The Fc receptor, which binds to both albumin and the 
Fc portion of IgG, was detected in the lymphatic vessels but not in the 
blood vessels of the conjunctiva. It may be that the function of the Fc 
receptor in the conjunctival lymphatic vessels is to act as an efflux 
receptor for the efficient elimination from the conjunctival space. 
Residual bevacizumab, other than the bevacizumab that directly 
permeated the sclera and was introduced into the blood circulation, may 
be eliminated from the conjunctival tissue into the lymphatic vessels via 
convective transport with lymphatic fluid.  
Systemic exposure of bevacizumab when administered by 
intravitreal and subconjunctival injection was very similar. 
Bevacizumab was detected in the fellow eyes treated by intravitreal or 
subconjunctival injection. Bevacizumab may have been transported 
through the systemic circulation into the fellow eyes. In the fellow eyes 
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treated by intravitreal injection, bevacizumab concentration in the 
retina/choroid was maintained above IC50 for 8.0 weeks. 
Heiduschka et al. demonstrated that bevacizumab can penetrate 
the retina and is transported into the retinal pigment epithelium, choroid, 
and photoreceptors after intravitreal injection using an 
immunohistochemical staining assay with donkey anti-human IgG. In 
that study, the antibody used for the detection of bevacizumab 
recognized the injected bevacizumab molecule specifically10.    
The strong intracorneal bevacizumab staining could persist for at 
least 3 days in the VEGF micropocket and alkali-induced corneal NV 
models after a single subconjunctival injection. The distribution of 
intracorneal bevacizumab could persist at least up to 7 days in the 
normal corneas. The reason for the different durations of intracorneal 
diffusion remains to be evaluated. Although not proven, the shorter 
duration of bevacizumab distribution in the vascularized corneas may be 
caused by the rapid absorption through the corneal vessels. In some 
studies, the eyes treated with bevacizumab showed significant decrease 
in the amount of neovascularization especially those treated with 
subconjunctival bevacizumab2&3. 
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TOPICALLY ADMINISTERED BEVACIZUMAB 
         While there is substantial evidence for the intravitreous 
administration of bevacizumab in the treatment of choroidal NV, data 
regarding the safety and efficacy of topical bevacizumab in the 
treatment of corneal NV are, as yet, preliminary. Topical bevacizumab 
was demonstrated to inhibit corneal NV after chemical injury in an 
experimental rat model. In humans, a small number of studies showed 
that topical bevacizumab can reduce corneal NV in a few patients with 
significant corneal NV. However, many aspects of topically 
administered bevacizumab in the treatment of corneal NV, including 
long-term safety and efficacy against actively growing as well as 
established corneal NV, optimal dosing for modulating the neovascular 
process, and long-term stability of treatment results, have not been well 
known.  
Although this reduction in neovascularization is significant, there 
is no complete regression of new vessel. This may be due to incomplete 
diffusion and absorption of the drug through the conjunctiva and due to 
washing out of the drug by the tear film and hence inadequate access to 
the ocular surface. Another reason is that bevacizumab inhibits only 
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VEGF and we know that fibroblast growth factor and other cytokines 
contribute to the pathology of neovascularization which cannot be 
inhibited by this drug. So inhibition of VEGF alone may not cause 
complete regression of the vessels, combination with steroids might 
cause complete regression of the vessels 15&16. 
In the case of subconjunctival injection, studies showed that most 
of the bevacizumab in the treated eyes was derived from the systemic 
circulation, and so the retinal and choroidal pharmacokinetics profile in 
the fellow eyes was similar to that in the treated eyes. In the fellow eyes, 
bevacizumab concentration in the retina/choroid was maintained above 
IC50 (inhibitory concentration) for 5.2 weeks. In the iris/ciliary body, a 
similar profile was observed, but in the fellow eye, bevacizumab was 
not detected at 12 weeks after injection. Of interest, corneal deposition 
of bevacizumab for 4 weeks after subconjunctival injection was 
observed by immunohistochemistry. Therefore, subconjunctival 
bevacizumab may be a promising treatment, not only for neovascular 
diseases of the iris, retina, and choroid but also for corneal 
neovascularization.4 
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SIDE EFFECTS OF SUBCONJUNCTIVALLY ADMINISTERED 
BAVACIZUMB 13  
SYSTEMIC SIDE EFFECTS 
      There are several reports that have noted the systemic adverse 
effects of bevacizumab after intravitreal injection. These adverse effects 
are similar to the ones reported for intravenous administration of 
bevacizumab for cancer treatment, such as systemic hypertension, 
thromboembolic diseases and death. In addition, Shima et al. found 
irregular vaginal bleeding as a complication in young women receiving 
intravitreal injection of bevacizumab.  It should be noted, however, that 
these were small studies with a small amount of participants. Systemic 
adverse effects of bevacizumab may occur after subconjunctival 
injection, as well as after intravitreal or intravenous injection. Therefore, 
intravitreal or subconjunctival bevacizumab should be used with caution 
in elderly patients with choroidal or iris neovascularization. However, 
efficacy in the fellow eye should be expected to derive from the 
systemic circulation.  
OCULAR SIDE EFFECTS 
Corneal epithelial defect, corneal ulcer, corneal oedema, 
Conjunctival necrosis, anterior uveitis, and Infectious endophthalmitis. 
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OTHER MODALITIES OF TREATMENT FOR CORNEAL 
NEOVASCULARISATION 
Current treatments for corneal NV including medications, such as 
steroids or non-steroidal anti-inflammatory agents, laser 
photocoagulation, fine-needle diathermy, photodynamic therapy, or 
restoration of the ocular surface with the use of conjunctival, limbal, or 
amniotic membrane transplantation have demonstrated variable and 
largely limited clinical success. 
  The highly variable efficacy and myriad side-effects (cataract, 
glaucoma, and increased risk of infection) of topical and systemic 
corticosteroids are well known to clinicians who use these agents 
regularly in trying to arrest these disease processes. Other treatment 
modalities are often ineffective, or vessel recanalization occurs requiring 
multiple treatment sessions which can lead to serious side effects. 
Furthermore, none of these treatments specifically target the molecular 
mediators of angiogenesis. 
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COST OF BEVACIZUMAB 
 The cost of single vial of bevacizumab (100mg/4ml) is 700$       
 
 
 
 
 
 
 
 
Fig. 7. Injection Avastin  
OTHER USES OF SUBCONJUNCTIVAL BEVACIZUMAB 
            There are ongoing studies to prove the effectiveness of 
subconjunctival injection of bevacizumab in managing 
9 highly vascular neoplasm of the conjunctiva such as conjunctival 
intra epithelial neoplasm (CIN)20 
9 highly vascularized pterygium       AND 
9 preventing bleb failure after glaucoma surgeries 
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PART II 
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                             AIM OF THE STUDY 
¾ To study the effect of subconjunctival Bevacizumab on corneal 
neovascularization in patients with 
1. Leucomatous opacity following exanthematous fever and post 
hydrops 
2. Pseudophakic bullous keratopathy  
3. Healed corneal ulcer  post trauma and infection 
4. Previously failed Optical keratoplasty 
¾ To evaluate regression of new vessels of cornea 
¾ To evaluate the safety and efficacy of subconjunctival injection of 
Bevacizumab  
¾ To evaluate the outcome of OKP after subconjunctival 
Bevacizumab    
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MATERIALS AND METHODS 
 This  study  was  done  in Cornea  Department Regional  Institute  
Of  Ophthalmology  And Government  Ophthalmic  Hospital  Chennai 
during  January 2009  To  January 2010.  
Twenty eyes of twenty patients with corneal neovascularization 
due to various pathologies (mentioned below) have been selected for the 
study. 
STUDY DESIGN 
` Interventional  
` Prospective 
` Non-Randomized clinical study  
 INCLUSION CRITERIA 
VASCULARISED CORNEAS OF PATIENTS WITH  
 Leucomatous opacity following exanthematous fever and post 
hydrops 
 Pseudophakic bullous keratopathy  
 Healed corneal ulcer post trauma and infection 
 Previously failed Optical keratoplasty  
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EXCLUSION CRITERIA 
 Patients with uncontrolled systemic hypertension with systolic 
blood pressure of  ≥150mm Hg or diastolic blood pressure of  ≥90 
mm of Hg 
 Patients with recent Myocardial Infarction 
 Patients with recent Cerebro Vascular Accidents 
 Diabetes mellitus 
 Renal, liver, and coagulation abnormalities including current 
anticoagulation medications 
 Current or recent systemic corticosteroid therapy or periocular 
corticosteroids injections to the study eye 
 Ocular or periocular malignancy 
 Pregnancy, lactating women, postmenopausal women not using 
adequate contraception 
 Any condition that precluded patients ability to comply with 
study requirements including completion of study 
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PROCEDURE 
Patients who were referred to cornea clinic with corneal 
neovascularization (mentioned above in inclusion criteria) were selected 
for the study.  
A brief history of all the patients were taken and subjected to 
detailed ocular and systemic examination. 
 Anterior segment examination was done with slit lamp 
biomicroscopy. Standardized corneal photographs were taken with 10X 
magnification with slit lamp biomicroscopy using digital camera.  
The off-label use of the drug and its benefits were discussed with 
all the patients. Informed consent was obtained. Detailed corneal 
drawings were done. 
NUMBER OF PATIENTS  
Twenty eyes of twenty patients with corneal neovascularization due 
to various pathologies (mentioned above) have been selected for the 
study.  
` Five eyes of 5 patients with healed fungal corneal ulcer 
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` Two eyes of  2 patients with Leucomatous opacity post 
exanthematous fever  
` Seven eyes of 7 patients with pseudophakic bullous keratopathy 
` Three eyes of  3 patients with previous failed keratoplasty due to 
vascularization  
` One eye with post hydrops (keratoglobus) 
`  Two eyes of  2 patients with post traumatic leucomatous opacity  
The off-label use of the drug and its potential risks and benefits 
were discussed extensively with all patients. All patients signed a 
comprehensive consent form before administration of the 
subconjunctival injection of bevacizumab. 
A commercially available bevacizumab (2.5mg/0.1ml, 100 mg/4 
mL) was prepared for each patient and placed in a tuberculin syringe 
using aseptic techniques. 
Topical anesthetics ( 4% xylocaine/ paracaine eye drops) and 
antibiotics are   applied  
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 The eye had been prepared with 5% povidone iodine in a standard 
fashion 
 Then draped with an eye mask 
 Opsite was applied 
 Using lid speculum eye was exposed 
 Bevacizumab (2.5mg/0.1ml)   was injected  subconjunctivally in 
the quadrant of vascularization 1cm from the limbus 
 Patients were instructed to apply antibiotic eye drops for 3 days 4 
times a day 
FOLLOW-UP  
Follow up visits were done on 14th day, 1st, 3rd, & 6th month post 
injection.  All the 20 patients completed 6 months of follow-up. At each 
visit patients were checked for regression of new vessels i.e. reduction 
in both number and caliber of the vessel. Patients were also examined 
for signs of graft rejection (those who have been operated) and side 
effects. 
 
54 
 
 MAIN OUTCOME MEASURES 
A. Regression of corneal new vessels 
B. Efficacy and safety of subconjunctival Bevacizumab 
C. Outcome of OKP after subconjunctival  Bevacizumab injection 
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10‐30 YEARS
51‐70 YEARS
5.5
6
6.5
7
10‐30 YEARS
31‐50 YEARS
51‐70 YEARS
OBSERVATIONS AND RESULTS 
                               TABLE 1; AGE DISTRIBUTION 
Total number of patients ─ 20 
Age distribution No of patients Percentage (%) 
10 – 30 yrs 6 30 
31 – 50 yrs 7 35 
51 – 70 yrs 7 35 
 
 
 
 
 
 
 
  In our study the upper age limit being 70 years and lower age 
limit being 15 years. The mean age was 42 years. 
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TABLE 2; SEX DISTRIBUTION 
Sex No of patients Percentage (%) 
Male 14 70 
Female 6 30 
                                                                                                           
Of the 20 patients who met the inclusion criteria for the study, 16 
were male and 4 were female. 
MALE: FAMALE ratio ≈ 2.3:1 
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TABLE 3: INDICATIONS 
Total number of patients ─ 20                 
Indication No of patients 
Percentage 
(%) 
Healed fungal corneal ulcer 5 25 
Leucomatous opacity –post exanthematous 
fever 
3 15 
Pseudophakic bullous keratopathy 6 30 
Previously failed OKP for regraft 3 15 
Post hydrops - keratoglobus 1 5 
Post traumatic leucomatous opacity 2 10 
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TABLE; 4 TIME OF INJECTION 
Indication Pre operative
Intra  
operative 
Post 
operative
Healed fungal corneal ulcer 4 1  
Leucomatous opacity – post 
exanthematous fever 
3   
Pseudophakic bullous keratopathy 5  1 
Previously failed OKP for regraft 3   
Post hydrops - keratoglobus   1 
Post traumatic leucomatous opacity 2   
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MAIN OUTCOME MEASURES 
A. REGRESSION OF CORNEAL NEW VESSELS 
Regression No of patients Percentage (%) 
Complete regression 10 50 
Partial regression 16 30 
No regression 4 20 
 
The reduction of corneal new vessels occurred to a different 
degree in each patient; 
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a. COMPLETE REGRESSION 
CASE – 1 
 
Leucomatous Opacity with Neovascularization 
Pre –injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 weeks post-injection 
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1 month post-injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3rd month post-injection 
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6th month post-injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This patient showed almost complete regression of the new vessels at 
the end of 6 months. 
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CASE-2  
 
Healed corneal ulcer 
Pre- injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 weeks post-injection 
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1 month post-injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 rd month post-injection 
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CASE-3 
 
Healed corneal ulcer with leucomatous opacity 
Injection given during keratoplasty 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 month post injection 
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3rd month post-injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CASE-4 
Pseudophakic Bullous Keratopathy 
Pre-Injection 
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3 Months Post-Injection 
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b. PARTIAL REGRESSION 
 
CASE-1 
Post Traumatic Leucomatous Opacity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 months pot injection 
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CASE-2 
 
Pseudophakic Bullous Keratopathy 
Pre-Injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Months post-injection 
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c. NO REGRESSION 
 
2 Months Post-Injection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 Months Post-Injection 
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B .SAFETY OF BEVACIZUMAB 
 
 Subconjunctival injection of Bevacizumb was well tolerated by 
all these twenty patients. 
 During this 6 months follow-up period none of the eyes 
developed any complication that could be related to 
subconjunctival injection of Bevacizumab.  
We found no corneal epithelial defect, corneal ulcer, corneal 
oedema, conjunctival necrosis, anterior uveitis, or infectious 
endophthalmitis related to subconjunctival injection in this study. 
However, the safety of bevacizumab on corneal cells is still an issue that 
needs to be considered. Yoeruek et al .demonstrated that bevacizumab is 
not toxic to corneal cells of human origin in vitro at doses normally used 
for treatment of corneal NV (up to 5.0 mg/ml), which is 20-fold higher 
than the dose used for intravitreous application. 
Kim et al. showed that topical application of bevacizumab causes 
spontaneous loss of corneal epithelial integrity and progression of 
stromal thinning. However, our study and others seem to support the 
conclusion that the subconjunctival delivery method is a good option for 
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inhibiting corneal NV. The delivery method is easy and simple to 
perform and leads to minimal related complications.  
C. COUTCOME OF OKP 
 Out of these 20 patients, 12 underwent optical keratoplasty 
and there was no immediate rejection during this 6 months 
follow-up period. 
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DISCUSSION 
  Corneal neovascularization remains a significant risk factor for 
corneal transplantation and subsequent graft failure after transplantation. 
The Collaborative corneal transplantation study identified, in addition to 
several other factors, the extent of stromal vessel (quadrants) 
involvement as a strong risk factor for corneal graft failure14.  
    Corneal neovascularization also affects millions of long term 
contact lens wearers, many of whom are forced to do reduce or 
discontinue contact lens use so that regression of corneal 
neovascularization may occur. 
 Various medications and surgical therapies have been attempted 
to reduce corneal angiogenesis including corticosteroids, non-steroidal 
anti inflammatory drugs, laser photocoagulation and needle diathermy. 
Many of these therapies are associated with adverse effects and risks, 
and most of these therapies have demonstrated limited success. 
Furthermore none of these treatments specifically target the inhibition of 
VEGF3&15. 
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 Anti-VEGF therapy, used to reduce corneal angiogenesis, has 
recently granted interest based on the successful results demonstrated 
with intravitreal bevacizumab. Preliminary in vivo animal data have 
shown the potential effectiveness of bevacizumab in treating corneal 
neovascularization. 
    Amino et al reported a potent suppression of corneal 
neovascularization after stromal implantation of anti-VEGF antibodies 
using a rat model. Ren et al also used a rat model to show the effects of 
topical bevacizumab (4mg/ml) in decreasing corneal neovascularization 
when applied twice daily for 1 week7. In topically administered 
bevacizumab there is no complete regression of the new vessels. This 
may be due to incomplete diffusion & absorption of the drug through 
the conjunctiva and due to washing out of the topical drug by the tear 
film & hence inadequate access to the ocular surface. Studies have 
proven that subconjunctival bevacizumab of 10mg is not superior to 
5mg in regression of new vessels3.  
         This is a 6 month prospective, non randomized clinical study to 
investigate the safety and efficacy of subcojunctival bevacizumab for 
the treatment of corneal neovascularization. 
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In this study an obvious reduction in established corneal 
neovascularization occurred to a different degree in each patient, and 
subconjunctival bevacizumab was well tolerated by all these patients. 
Out of 20 patients in 50% 0f patients complete regression of the corneal 
new vessels noted at the end of 6th month. Whereas in 30% of patients 
only partially reduction noted i.e. reduction in calibre of vessels only, 
the number of new vessels was constant. In 20% of patients both 
number of new vessels and the calibre was constant. All these 4 patients 
had large calibered vessels and the duration of the disease process was 
also long.  
    This variable response may be because of the chronicity, extent 
of corneal neovascularization, amount of scarring, disease process, 
formulation and route of administration of the drug 15&16. 
   Successful  reduction of corneal neovascularization with 
subconjunctival anti-VEGF therapy could play an important role in 
improving graft survival in patients who have pre-existing corneal 
neovascularization  (NV) or NV of the peripheral cornea that develops 
after penetrating keratoplasty. The reduction or elimination of corneal 
NV could therefore allow for corneal transplantation17 in those patients 
who were previously considered high risk and had contraindication to 
surgery.                                      
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REVIEW OF LITERATURE 
The  off-label use of topical as well as subconjunctival 
bevacizumab has also been considered as a new treatment modality for 
corneal NV.  
 
Corneal neovascularization (NV) due to aqueous-deficient dry eye with filamentary 
keratitis (a). It was rapidly resolved, one week after subconjunctival bevacizumab 
injection (b). No relapse was seen at the end of three months of follow-up (c) 
 
 
 
Corneal neovascularization (NV) due to corneal graft failure (a). Minor branches of 
the corneal neovascularization appear to be rapidly resolved one week after 
subconjunctival bevacizumab injection (b), while the major branch did not markedly 
regress within the two months of follow-up (c) 
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    Briefly, a dramatic regression of corneal NV in all eyes was 
confirmed by slit-lamp biomicroscopy within just a week after injection 
and no relapse was seen within the follow-up period of 2–3 months. In 
this study they used 2.5 mg (0.1 ml) of bevacizumab solution for corneal 
NV in patients. The results suggested that this dosage may be enough 
for corneal NV and could be repeated if necessary. Although some 
portion of bevacizumab might have been passed into the systemic 
circulation via subconjunctival vessels, a sufficient amount seemed to be 
maintained to lessen the corneal NV7.  
 Our study findings provide evidence that anti-VEFG therapy 
could potentially offer a safer and effective alternative to conventional 
therapies in treating corneal neovascularization without potential 
adverse effects. The initial impressive short term response and the high 
tolerance to subconjunctival bevacizumab therapy offer encouraging 
results for the potential role of subconjunctival anti-VEGF therapy in 
treating corneal diseases associated with corneal NV.  
 
78 
 
CONCLUSION 
¾ Subconjunctival  injection of Bevacizumab can be used safely and 
effectively for corneal neovascularization resulting from different 
types of disorders. 
¾ It may provide an additional strategy in improving success of 
corneal grafts in these patients. 
¾ This is a short term study. However long-term follow-up is 
necessary to determine whether repeat injections are necessary. 
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  PROFOMA 
Case No; 
Name  
Age  
Sex 
Occupation 
Op No 
Cornea Clinic No 
Phone No 
Address 
Chief Complaints 
Pain, watering, photophobia                     Eye; 
Defective vision 
Opacity 
Duration 
Past History 
 
History of injury 
History of previous surgeries 
Diabetes 
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Hypertension –    No of years 
                            On what medications 
                Associated with ischemic heart disease  
   Cerebrovascular insults 
                            Anticoagulant intake 
 
History of smoking 
Systemic Examination 
PR;                                            BP;                           RBS;   
Ocular Examination 
Visual acuity before and after dilatation 
Intraocular pressure 
Slit Lamp Examination 
 
Conjunctiva  
Cornea  – extent of corneal opacity & neovascularization drawn with 
colour pens, photographs taken. 
Anterior chamber 
 Iris 
Pupil 
Lens 
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Dilatation and fundus by 90D with Slit Lamp and Indirect 
Ophthalmoscopy 
 
DIAGNOSIS; 
Treatment history 
             Under aseptic precautions, under topical anaesthesia injection 
bevacizumab 2.5mg (0.1ml) injected in   _____________                              
quadrant.   
OUTCOME OF TREATMENT; 
 present absent 
Decrease in no of vessels + - 
Decrease in calibre of vessels + - 
Signs of rejection + - 
Side effects + - 
 
 
CONSENT; 
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KEY TO MASTER CHART 
 
M              -  Male 
F                - Female 
C.C NO   - Cornea Clinic Number 
LE             - Left Eye 
RE            - Right Eye 
PBK         - Pseudophakic Bullous Keratopathy 
FCU         - Fungal Corneal Ulcer 
LEUCP   - Leucomatous Opacity Post Chicken Pox 
PO TR      - Post Trauma 
HYD LEUC - Post Hydrops with Leucomatous Opacity 
REGRAFT  - Previously failed graft for repeat OKP 
OKP         - Optical Keratoplasty  
INJCN      -  Bevacizumab Injection given 
PO             - Prior to OKP 
DO             - During OKP 
AO             - After OKP 
WL            - Weeks Later 
ML             - Months Later 
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N↓              - Reduction in the number of the vessels 
C↓               - Reduction in the Calibre of vessel 
REJCN       - Signs of graft Rejection 
S.E              - Side Effects                     
+                   - Present 
-                    - Absent 
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                 LIST OF SURGERIES PERFORMED 
 
S. 
No Name Age Sex IP No Diagnosis Surgery 
1 Shantha  65 F 693412 BE-MC RE-ECCE with 
PCIOL 
2 Karpagam 70 F 683675 BE-MC RE-ECCE with 
PCIOL 
3 Sundaram 60 M 727681 RE-IMC LE-MC RE-ECCE with 
PCIOL 
4 Dhanalakshmi 55 F 732612 RE-IMC LE-MC LE-ECCE with 
PCIOL 
5 Govindan  65 M 757345 RE –PSEUD/LE 
MC 
LE-ECCE with 
PCIOL 
6 Nagarajan 56 M 785492 RE-MC RE-ECCE with 
PCIOL 
7 Rahimbee 55 F 790053 LE-IMC LE-ECCE with 
PCIOL 
8 Kannamma 70 F 820789 RE-MC RE-SICS with 
PCIOL 
9 Shiva 64 M 853412 RE-PSEUD/LE 
IMC 
LE-SICS with 
PCIOL 
10 Sundar  59 M 87720 RE-IMC RE-SICS with 
PCIOL 
11 Rani 65 F 89558 LE-IMC LE-SICS with 
PCIOL 
12 Prema 54 F 90567 RE-IMC RE-SICS with 
PCIOL 
89 
 
13 Balu 50 M 640091 LE-IMC LE-SICS with 
PCIOL 
14 Hema 49 F 543781 RE-IMC RE-PHACO with 
PCIOL 
15 Sukumar 50 M 549834 LE-IMC LE-PHACO with 
PCIOL 
16 Ramachandran 65 M 65479 RE-IMC RE-PHACO with 
PCIOL 
17 Yesudass 69 M 98712 RE-POST OP 
ENDOPH 
INTRAVITREAL 
ANTIBIOTICS 
18 Saroja 76 F 25378 RE-PANOPH RE-
EVISCERATION
19 Alagiri 60 M 65498 LE-CDC LE-DCT 
20 Subramni 55 M 76594 RE-CDC RE-DCT 
21 Anandh 62 M 69831 RE-FUNGAL 
CORNEAL 
ULCER 
RE-TKP 
22 Visalam 60  F 72254 RE 
PERFORATED 
ULCER 
RE-TKP 
23 Sumathi 45 F 76583 RE-CORNEAL 
ULCER 
RE-TKP 
24 Ramachandran 75 M 35471 LE-
PTERYGIUM 
RE-EXCISION 
withAMG 
25 Rajamani 55 M 37659   
26 Lakshmi 30 F 275498 RE-ABSOLUTE 
GLAUCOMA 
RE-TRAB  
90 
 
27 Rajendran 44 M 65890 LE-CDC LE-DCR 
28 Meenakshi 45 F 78659 RE-CIN EXCISION 
29 Kaliammal 68 F 28779 RE-
EXP.KERATITIS
RE-LATERAL 
TARSORRAPHY
30 Mary 57 F 79463 RE- CORNEAL 
ULCER 
RE-TKP 
 
N↓ C↓ REJCN S.E N↓ C↓ REJCN S.E N↓ C↓ REJCN S.E N↓ C↓ REJCN S.E
1
Appayee
70 M 917 RE-PBK PO 2WL      +      +      -      -    +      +      -      -     +      +      -     -    -    -       -     -
MASTER CHART
6 MONTHS POST INJECTION
S. No. NAME AGE SEX C.C NO DIAGNOSIS INJCN OKP
2 WEEKS POST INJECTION 1 MONTH POST INJECTION 3 MONTHS POST INJECTION
2
Murugan
30 M_ 1540 LE-FCU PO 5ML      +      +      -    +      +      -     +      +      -      -    -    -       -     -
3
Selvaraj  
55 M 1095 LE-LEUCP DO      +      +      -      -    +      +      -      -     +      +      -      -    -    -       -     -
4
Lakshmi
22 F 3657 RE-HYD LEUC AO      +      +      -      -    +      +      -      -     +      +      -      -    -    -       -     -
5
Mohammadh
62 M 4283 RE-PBK PO 3ML      +      +      -    +      +      -     +      +      -      -    -    -       -     -
6
Elumalai
50 M 4074 RE-REGRAFT PO 5ML      +      +      -    +      +      -     +      +      -    -    -       -     -
7
Vasantha
48 F 803 RE-PBK      +      +      -    +      +      -     +      +      -    -    -     -
8
Hussein
58 M 3427 RE-PBK PO 1ML      +      +      -    +      +      -      -     +      +      -      -    -    -       -     -
9
Muniyandi
35 M 1611 RE-PO TR PO 1ML      +      +      -      -    +      +      -      -     +      +      -      -    -    -       -     -
10
Allma
68 F 2361 LE-REGRAFT AO      +      +      -      -    +      +      -      -     +      +      -      -    -    -       -     -
11
Surendarsing
32 M 560 LE-LEUCP PO 3ML      -      +      -      -      +      -      -      +      -      -    -    -       -     -
12
Babu
46 M 718 LE-TEGRAFT PO 3ML      -      -      -      -      -      -      -      -      -      -    -    -       -     -
13
Shankar
30 M 296 RE-PO TR PO      -      +      -      -      +      -      -      +      -    -    -     -
14
Sunder
25 M 415 RE-FCU PO      -     +     -     -     +     -     -     +      -    -   -    -
15
Hari
69 M 1290 LE-PBK PO 2ML      -      -      -      -      -      -      -      -      -      -    -    -       -     -
16
Patchaiyappan
50 M 1536 RE-LEUCP PO      -      +      -      -      +      -      -      +      -    -    -     -
17
Srinivasan
47 M 1772 LE-FCU PO      -      -      -      -     -      -      -      -      -    -    -     -
18
Dilipkumar
25 M 2837 RE-FCU PO      -      +      -      -      +      -      -      +      -    -    -     -
19
Akila
15 F 2165 LE-FCU PO      -      +      -      -      +      -      -      +           -      -      -
20 65 M 1559 RE-PBK PO - - - - - - - - - - - -
